RedHill Biopharma Ltd. (RDHL)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Dror Ben-Asher | Co-Founder, Chairman & CEO | 594.61k | -- | 1966 |
| Mr. Razi Ingber | Chief Financial Officer | 339.82k | -- | 1984 |
| Mr. Gilead Raday MPhil, MSc | Chief Operating Officer | 365.56k | -- | 1975 |
| Mr. Adi Frish | Chief Corporate & Business Development Officer | 339.3k | -- | 1970 |
| Mr. Rick D. Scruggs | Chief Commercial Officer, President of RedHill Biopharma Inc. & Director | 469.8k | -- | 1960 |
| Ms. Alexandra Okmian | Senior Business Development & Investor Relations Manager | -- | -- | -- |
| Dr. Reza Fathi Ph.D. | Senior Vice President of Research & Development | 299.29k | -- | 1955 |
| Mr. Guy Goldberg J.D. | Chief Business Officer | 338.13k | -- | 1976 |
| Dr. June S. Almenoff FACP, M.D., Ph.D. | Chief Medical Officer | -- | -- | 1957 |
| Ms. Patricia Anderson B.Sc. RAC | Senior Vice President of Regulatory Affairs | -- | -- | -- |
RedHill Biopharma Ltd.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 53
Description
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Corporate Governance
Recent Events
- Apr 18, 2024POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filingSee Full Filing
- Apr 08, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 04, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 02, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 21, 20246-K: Corporate Changes & Voting MattersSee Full Filing